by Evelyn Ma | Sep 8, 2026 | Blog
Why Kinase Selectivity Demands Multiple Assay Formats The human kinome comprises more than 500 kinases sharing a conserved ATP-binding pocket and high structural homology. This conservation is the central obstacle in kinase drug discovery: a compound potent against...
by Evelyn Ma | Aug 1, 2026 | Blog
Participants: Haiching Ma, PhD (Founder & CSO, Reaction Biology), Jason Amsbaugh, MBA (CEO, Samba Scientific), Trent Carrier, PhD, MBA (CEO, Carolina Molecular) Overview Reaction Biology is celebrating its 25th anniversary this year, having grown from a small...
by Evelyn Ma | Mar 26, 2026 | Blog
Over 100 kinase inhibitors have now been approved by the FDA, transforming the treatment of cancer and other diseases.¹ Yet despite this progress, a key question remains underexplored: can these drugs be repurposed to target newly identified oncogenic kinase variants...
by Evelyn Ma | Feb 19, 2026 | Blog
Immunological impact across diseases Far more therapeutic areas involve immune regulation than traditional disease boundaries have suggested, leading to practical implications for how we profile drug candidates. Already a staple in immuno-oncology, autoimmune,...
by Evelyn Ma | Jan 26, 2026 | Blog
At Reaction Biology, quality is a commitment we can measure. We hold ourselves accountable for data integrity and report delivery metrics that define a quantifiable standard for our scientific operations. These performance metrics govern how we generate and deliver...
by Simon Clarke | Oct 13, 2025 | Blog
PPI biology balances promise and risk Protein-protein interactions (PPIs) are at the center of many critical cellular processes. They guide signaling, regulate gene expression, and ensure the smooth coordination of biological pathways. Dysregulation and disruption of...
